Michael Altorfer, CEO of the Swiss Biotech Association, outlines the role of Swiss biotechnology companies in the the "BioTechnologie Jahrbuch 2020"
Switzerland is making an important and effective contribution in the global response to the COVID pandemic.The Swiss biotech industry worked closely with leading research laboratories, hospitals, diagnostic companies, drug manufacturers and multinational pharmaceutical companies. This achievement has highlighted the importance of this industry to the public and many decision-makers. In the shadow of COVID, numerous biotech companies were able to close important financing rounds and complete research collaborations. In many indications, project progress has been made. Among others, an application for approval of a first compound for the treatment of Alzheimer's disease was submitted.